Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease-Reference-Cited by-同舟云学术

Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease

Published:2024-03-26 Issue:4 Volume:30 Page:1199-1209
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Agarwal Anubha^ORCID,Mehta Priya M.^ORCID,Jacobson Tyler^ORCID,Shah Nilay S.,Ye Jiancheng,Zhu JingJing,Wafford Q. Eileen,Bahiru Ehete,de Cates Angharad N.,Ebrahim Shah,Prabhakaran Dorairaj,Rodgers Anthony,Huffman Mark D.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Doris Duke Charitable Foundation

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-02896-w.pdf

Reference58 articles.

1. Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021 (2020).

2. Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795–808 (2020).

3. The Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273–1285 (2023).

4. Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937–952 (2004).

5. Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects;Drug Design, Development and Therapy;2024-07